2017 American Transplant Congress
Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.
1UPENN, Philadelphia, PA; 2Yale, New Haven, CT
Background: New HCV drugs could reduce the risks of donor-derived HCV infection. However, it is unknown if HCV-negative (HCV-) ESRD patients would accept an HCV+…2017 American Transplant Congress
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
Multi Transplant Organ Center, St Vincent Medical Center, Los Angeles, CA
Reports of efficacy of Direct Acting Antiviral drugs (DAA) > 90% in treatment of chronic HCV genotype 1, [GT1, 12 wk Sustained Viral Response (SVR12)]…2017 American Transplant Congress
Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.
Background Less than 0.2 % of initially NAT(+) upon retesting are reported as NAT negative. However, there is a concern that these results could be…2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.
Dermatology, Drexel, Philadelphia
Purpose: HIV and HCV are two immune dysregulatory processes that may exacerbate the risk of nonmelanoma skin cancer (NMSC) in organ transplant recipients (OTR), a…2017 American Transplant Congress
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach…2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…2016 American Transplant Congress
Inferior Outcomes in Hepatitis C Virus Positive Donors to Hepatitis C Virus Negative Kidney Recipients: Analysis of National Data.
Virginia Commonwealth University, Richmond, VA.
Background: Kidney transplantation (KTxp)with HCV kidneys (HCV D+)may represent a safe resource to expand the donor pool, and to reduce waiting time in patients with…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Quantitative Hepatitis C Virus (HCV) RNA in Plasma and Kidney Tissue in HCV Antibody Positive Donors.
Background: Currently HCV antibody positive deceased donors renal allografts are not considered for transplantation in HCV negative recipients. With recent development of anti-HCV therapy, utilization…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 28
- Next Page »